13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001281446
Total reported value
$529.1M
$529.1M
42 檔
25.5%
The Q1 2026 SEC filing reveals that Great Point Partners LLC held a total portfolio value of $529.1M, covering 42 public equity positions.
In Q1 2026, Great Point Partners LLC displayed an active expansion posture, initiating 21 new positions and adding to 8 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | Stock-Other | 7.23% | -7.23% | EXIT | |
| 2 | VOR | Vor Biopharma Inc | Stock-Other | 7.18% | -1.27% | +27.73% | |
| 3 | ✓ | Zura Bio LTD | Stock-Other | 5.77% | -1.07% | +10.48% | |
| 4 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 5.59% | -3.21% | — | |
| 5 | IBRX | Immunitybio Inc | Stock-Healthcare | 5.29% | -0.32% | — | |
| 6 | NKTR | Nektar Therapeutics | Stock-Other | 5.23% | -2.92% | +50.17% | |
| 7 | ✓ | Stock-Other | 5.00% | -1.16% | — | ||
| 8 | ALMS | Alumis Inc | Stock-Other | 4.33% | +0.22% | — | |
| 9 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 3.69% | -2.24% | — | |
| 10 | ANNX | Annexon Inc | Stock-Other | 3.18% | +0.60% | — | |
| 11 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.12% | -3.12% | EXIT | |
| 12 | IMVT | Immunovant Inc | Stock-Other | 3.11% | -3.11% | EXIT | |
| 13 | JBIO | Jade Biosciences Inc | Stock-Other | 3.11% | -3.11% | EXIT | |
| 14 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 2.40% | +0.45% | +0.02% | |
| 15 | ZBIO | Zenas Biopharma Inc | Stock-Other | 2.35% | -2.35% | EXIT | |
| 16 | NGNE | Neurogene Inc | Stock-Other | 2.32% | -0.23% | +42.86% | |
| 17 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.14% | +1.01% | — | |
| 18 | CLYM | Climb Bio Inc | Stock-Other | 2.10% | +0.36% | +36.20% | |
| 19 | ORKA | Oruka Therapeutics Inc | Stock-Other | 2.07% | +1.23% | — | |
| 20 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 2.00% | -0.50% | — | |
| 21 | VERA | Vera Therapeutics Inc | Stock-Other | 1.84% | +3.03% | — | |
| 22 | EVMN | Evommune Inc | Stock-Other | 1.72% | -0.90% | — | |
| 23 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 1.70% | +0.25% | — | |
| 24 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.64% | -1.64% | EXIT | |
| 25 | SCYXEUR | Scynexis Inc | Stock-Other | 1.59% | -1.59% | EXIT | |
| 26 | PALI | Palisade Bio Inc | Stock-Other | 1.37% | -0.47% | — | |
| 27 | CNTX | Context Therapeutics Inc | Stock-Other | 1.35% | -1.35% | EXIT | |
| 28 | RLMD | Relmada Therapeutics Inc | Stock-Other | 1.35% | -0.25% | — | |
| 29 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.24% | -0.31% | +26.29% | |
| 30 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 1.20% | -1.20% | EXIT | |
| 31 | TENX | Tenax Therapeutics Inc | Stock-Other | 1.20% | -1.20% | EXIT | |
| 32 | PMN | Promis Neurosciences Inc | Stock-Other | 1.08% | -0.87% | — | |
| 33 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.98% | +0.05% | -52.68% | |
| 34 | IMMX | Immix Biopharma Inc | Stock-Other | 0.73% | +1.76% | — | |
| 35 | RZLT | Rezolute Inc | Stock-Other | 0.67% | +0.27% | — | |
| 36 | PHVS | Pharvaris N.V. | Stock-Other | 0.54% | -0.54% | EXIT | |
| 37 | HUMA | Humacyte Inc | Stock-Other | 0.52% | +0.03% | — | |
| 38 | GALT | Galectin Therapeutics Inc | Stock-Other | 0.51% | +0.19% | — | |
| 39 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.43% | -0.43% | EXIT | |
| 40 | ALKS | Alkermes plc | Stock-Healthcare | 0.41% | -0.41% | EXIT | |
| 41 | AVXL | Anavex Life Sciences CORP | Stock-Other | 0.37% | -0.11% | — | |
| 42 | IRD | Opus Genetics Inc | Stock-Other | 0.34% | +1.19% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NKTR | Nektar Therapeutics | +2.3% | +50.17% | Add |
| 2 | VOR | Vor Biopharma Inc | +1.4% | +27.73% | Add |
| 3 | CLYM | Climb Bio Inc | +0.8% | +36.20% | Add |
| 4 | ORKA | Oruka Therapeutics Inc | +0.3% | — | Unchanged |
| 5 | NGNE | Neurogene Inc | 0% | +42.86% | Add |
| 6 | RZLT | Rezolute Inc | -0.1% | — | Unchanged |
| 7 | EVMN | Evommune Inc | -0.1% | — | Unchanged |
| 8 | PHVS | Pharvaris N.V. | -0.2% | — | Unchanged |
| 9 | UNCY | Unicycive Therapeutics Inc | -0.3% | — | Unchanged |
| 10 | AVTX | Avalo Therapeutics Inc | -0.3% | — | Unchanged |
| 11 | SLN | Silence Therapeutics Plc-adr | -0.4% | +26.29% | Add |
| 12 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.5% | -1.55% | Trim |
| 13 | CTNM | Contineum Therapeutics Inc-a | -0.6% | +0.02% | Add |
| 14 | ✓ | Zura Bio LTD | -0.7% | +10.48% | Add |
| 15 | CNTX | Context Therapeutics Inc | -0.9% | -52.21% | Trim |
| 16 | JBIO | Jade Biosciences Inc | -0.9% | +19.62% | Add |
| 17 | EPRX | Eupraxia Pharmaceuticals Inc | -0.9% | — | Unchanged |
| 18 | CGEM | Cullinan Therapeutics Inc | -1.2% | -52.68% | Trim |
| 19 | AMLX | Amylyx Pharmaceuticals Inc | -1.3% | — | Unchanged |
| 20 | APGE | Apogee Therapeutics Inc | -1.9% | — | Unchanged |
| 21 | IMVT | Immunovant Inc | -3.1% | -27.25% | Trim |
| 22 | IBRX | Immunitybio Inc | — | NEW | New buy |
| 23 | ✓ | — | NEW | New buy | |
| 24 | IRON | Disc Medicine Inc | — | EXIT | Sold out |
| 25 | RAPT | Rapt Therapeutics Inc | — | EXIT | Sold out |
| 26 | ALMS | Alumis Inc | — | NEW | New buy |
| 27 | SLNOEUR | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 28 | DRUG | Bright Minds Biosciences Inc | — | NEW | New buy |
| 29 | DNTH | Dianthus Therapeutics Inc | — | EXIT | Sold out |
| 30 | ANNX | Annexon Inc | — | NEW | New buy |
| 31 | ZBIO | Zenas Biopharma Inc | — | NEW | New buy |
| 32 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 33 | FULC | Fulcrum Therapeutics Inc | — | EXIT | Sold out |
| 34 | UPB | Upstream Bio Inc | — | EXIT | Sold out |
| 35 | VERA | Vera Therapeutics Inc | — | NEW | New buy |
| 36 | LBRX | Lb Pharmaceuticals Inc | — | NEW | New buy |
| 37 | CMPX | Compass Therapeutics Inc | — | NEW | New buy |
| 38 | SCYXEUR | Scynexis Inc | — | NEW | New buy |
| 39 | RARE | Ultragenyx Pharmaceutical In | — | EXIT | Sold out |
| 40 | PALI | Palisade Bio Inc | — | NEW | New buy |
| 41 | RLMD | Relmada Therapeutics Inc | — | NEW | New buy |
| 42 | TENX | Tenax Therapeutics Inc | — | NEW | New buy |
| 43 | PMN | Promis Neurosciences Inc | — | NEW | New buy |
| 44 | IMMX | Immix Biopharma Inc | — | NEW | New buy |
| 45 | SANA | Sana Biotechnology Inc | — | EXIT | Sold out |
| 46 | HUMA | Humacyte Inc | — | NEW | New buy |
| 47 | GALT | Galectin Therapeutics Inc | — | NEW | New buy |
| 48 | ALKS | Alkermes plc | — | NEW | New buy |
| 49 | AVXL | Anavex Life Sciences CORP | — | NEW | New buy |
| 50 | IRD | Opus Genetics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Great Point Partners LLC reported a total U.S. public equity portfolio value of $529.1M across 42 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including APGE, VOR, ZURA BIO LTD) accounted for 25.5% of total reported equity market value during Q1 2026.
Top New Position Initiated
IBRX
市值: $23.0M
Top Position Liquidated / Trimmed
IRON
前期市值: $19.9M
During Q1 2026, Great Point Partners LLC's top holdings by market value included APGE (7.2%)、VOR (7.2%)、ZURA BIO LTD (5.8%). The largest single position, APGE, represented 7.2% of total portfolio value.
In Q1 2026, Great Point Partners LLC made 41 total portfolio adjustments, initiating 21 new buys, adding to 8 positions, trimming 4 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.